HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BO-0742

a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Acridines: 325
      - BO-0742: 1
Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - BO-0742: 1

Experts

1.	Chou, Ting-Chao: 1 article (04/2009)
2.	Lee, Chien-Hsin: 1 article (04/2009)
3.	Shao, Li-En: 1 article (04/2009)
4.	Su, Tsann-Long: 1 article (04/2009)
5.	Yu, Alice L: 1 article (04/2009)
6.	Yu, John: 1 article (04/2009)

Related Diseases

1.	Neoplasms (Cancer) 04/18/2009 - "This is a preclinical study of BO-0742, a derivative of 3-(9-acridinylamino)-5-hydroxymethyl-aniline (AHMA) and N-mustard, as an anti-cancer agent. " 04/18/2009 - "Thus, BO-0742 is a potent anti-cancer agent worthy of further clinical development." 04/18/2009 - "BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors." 04/18/2009 - "MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors. "
2.	Ovarian Neoplasms (Ovarian Cancer) 04/18/2009 - "Administration of BO-0742 at an optimal dose schedule based on its pharmacokinetics significantly suppressed the growth of xenografts of human breast and ovarian cancers in mice. "
3.	Neuroblastoma 04/18/2009 - "MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors. "
4.	Leukemia 04/18/2009 - "BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors." 04/18/2009 - "MTS assays revealed a broad spectrum of anti-cancer activities in vitro, with the greatest cytotoxicity against leukemia and neuroblastoma including those with drug resistant characteristics, and a good therapeutic index with leukemia being 10-40 times more sensitive to BO-0742 than hematopoietic progenitors. "